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Abstract
Background: Patients with interatrial communications after paradoxical embolic events are at risk
for recurrent thromboembolism. We hypothesized that transcatheter closure of the defects would
result in long-term prevention of systemic embolism and performed clinical and echocardiographic
follow-up.
Methods: We included 161 patients (mean age 46.8 ± 11 years, 83 females) with patent foramen
ovale or atrial septal defect and at least one documented paradoxical systemic thrombembolic
event and/or a large atrial shunting.
Results: The implantation procedure was successfully performed without major complications in
all patients and minor complications in 2.5%. Two and / or three dimensional echocardiography was
performed before and after 4 weeks and 12 months using a multiplane transoesophageal probe.
After 4 weeks and 6 months two patients had minimal shunting. These residual defects were closed
with a second device implantation without shunting after further 4 weeks. During a follow-up of
324.3 patient years (range, 13 to 19 months), recurrent embolic events occurred in only 1 patient
(0.6%).
Conclusion: After primary paradoxical systemic embolism, results of transcatheter occlusion of
the interatrial communications are dependent on the closure device system and can prevent
further secondary embolic events for up to 1 year after the percutaneous closure. Three
dimensional echocardiography provides dynamic features of the defects and the post closure status
and may lead to an improved understanding and diagnosis of the interatrial defect.
Introduction
Atrial septal defect (ASD) and patent foramen ovale
(PFO) are the most common cardiac abnormalities. They
predispose to cerebral ischemia as a result of paradoxical
thromboembolism by right-to-left shunting under condi-
tions or physiologic maneuvers that raise right atrial pres-
sure [1,2]. Several studies using contrast
echocardiography established a strong association
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between cryptogenic stroke and the presence of PFO in
young adults < 55 years old [1,3,4]. Stroke databases sug-
gest that despite intensive evaluation, approximately 40%
of all patients suffering ischemic strokes without a clearly
identifiable cause [5]. The term "presumed paradoxical
embolism" is used for patients after exclusion of all
known causes of arterial thrombosis and thrombembo-
lism (atherosclerosis, atrial arrhythmia). There is a strong
correlation between PFO and primary occurrences of
strokes [6]. The risk of recurrent cerebrovascular events is
increased in patients with PFO combined with atrial sep-
tum aneurysm [7]. Patients with interatrial communica-
tions and paradoxical embolism are also at increased risk
for recurrent thrombembolic cerebral events in up to
3.8% per year [8].
An optimal secondary stroke prevention strategy in
patients with ASD and/or PFO is not clearly defined [9].
Percutaneous closure of the interatrial communication,
surgical closure of the defects, or oral anticoagulation in
patients with small defects (with only small shunt vol-
ume) are alternatives for secondary prevention of recur-
rent thromboembolic events. There is an increased risk for
subsequent ischemic cerebral events despite anticoagulant
therapy if an interatrial communication was diagnosed by
transesophageal contrast echocardiography [10], thus
demonstrating the need for alternative therapies. Surgical
ASD or PFO closure has been proven feasible, but includes
thoracotomy and heart-lung machine. The results have
been mixed with respect to stroke prevention [11]. There-
fore, different devices for nonsurgical, transcatheter defect
closure have been developed recently [12,13].
The selection of patients for transcatheter closure of atrial
septal defects requires accurate information regarding the
anatomy, size and topography of the defect.
Percutaneous defect closure is possible with a variety of
different devices. In the USA, PFOs may be closed percu-
taneously under the Food and Drug Administration man-
dated humanitarian device exemption (HDE) guidelines
in limited specific circumstances, both with CardioSEAL
and the Amplatzer PFO Occluder. Assessing the efficacy of
percutaneous closure for each device has been trouble-
some for different reasons: the case series nature of exist-
ing studies, lack of randomised trials, as well as a lack of
defined and clinically meaningful end points. The early
experiences with the Clamshell device resulted in 4 recur-
rent TIA after 24 months in 28 patients [14]. In a multi-
centre trial using the ASDOS device, recurrent TIA
occurred in only 1 of 46 patients with PFO with a high rate
of peri- and postprocedural complications [15]. Trans-
esophageal echocardiography is the preferred method for
pre-procedural and follow-up examination. Three-dimen-
sional (3D) echocardiography is a new diagnostic tech-
nique to obtain additional anatomic details of ASD in
vivo and, thus, predict the procedural success of ASD clo-
sure and detect post procedural complications.
Placement of a device does not mean that all antithrom-
botic agents can be halted [5]. No benefit-risk ratio for
transcatheter closure has been established yet. So far
descriptive series have been followed only by additional
case-control studies, without the prospective collection of
primary occurrences of cryptogenic strokes and PFOs
[16,17].
Choice, duration, and benefit and risks of peri- and post-
implant antiplatelet or anticoagulant therapy remains
unclear and undefined. A combination of aspirin and
clopidogrel for 6 months according to the post-coronary
stent implantation regime was used in most patients. Sys-
tematic reviews could demonstrate that percutaneous
PFO closure has a protective effect on stroke and TIA
recurrence compared with medical treatment: after the
first year, for 23 patients one stroke or TIA was prevented
compared to medical treatment alone [18].
However, given a high procedural success rate and a low
number of residual shunts in the present study and in the
study by Bruch et al. [19], the percutaneous closure of
interatrial defects may become the favourable method
after paradoxical embolism.
There are considerable differences between studies regard-
ing surgical closure of defects with a recurrence rate of
stroke or TIA between 7.5% after 12 months [20] and
19.5% within 13 months [21]. The different surgical tech-
niques and patient selection criteria may explain this
white range of embolism recurrence.
Throughout the past decade, a number of randomized
controlled trials including the percutaneous closure trial
and the Paradoxical Embolism Prevention Study in
Ischemic Stroke (PEPSIS) trial were attempted but have
failed. New trials are currently performed, and will likely
contribute to answer the necessary scientific and clinical
questions to allow for improved patient care. CLOSURE-
1, is a trial with more than 1600 patients which tests the
superiority of the CardioSEAL-STARFlex versus the best
medical treatment, evaluating neurologic end points. A
second trial, RESPECT, evaluates the equivalency of
Amplatzer PFO Occluder with clinician-determined best
medical therapy in patients after stroke.
Adams [22] concluded that none of the therapeutic
options could be recommended if the rules of evidence
are used to assess the current data. This study prospec-
tively assesses the success rate, the risk for recurrent cere-
brovascular events, and the diagnostic value of two-Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/5
Page 3 of 10
(page number not for citation purposes)
dimensional and three-dimensional transesophageal
echocardiography before and after percutaneous, tran-
scatheter closure of interatrial communications with a
variety of devices in consecutive patients after paradoxical
cerebrovascular events.
Methods
Patient population
Between May 1993 and December 2002, percutaneous
closure of interatrial communications was performed at
our institution in 161 patients with a PFO or ASD (mean
age 46.8 ± 12.9 years; range 19 to 78 years) and ≥ 1 docu-
mented thromboembolic events or a pulmonary-to-sys-
temic flow ratio by oximetry (Fick method) of at least
1.5:1 and/or symptoms of right-sided volume overload.
The patients were referred from stroke units. A throm-
boembolic event was considered to be due to paradoxical
embolism if the following criteria were met: (1) presence
of PFO (with or without septal aneurysm) or ASD with
spontaneous or provocable right-to-left shunt during con-
trast transesophageal echocardiography, (2) clinically and
neurologically confirmed ischemic stroke or symptoms of
transient ischemic attack with neuroradiologically identi-
fied intracranial ischemic or clinically and radiologically
verified extracranial peripheral thromboembolism; and
(3) exclusion of any identifiable cause for the throm-
boembolic event other than the interatrial communica-
tion (Table 1). All patients gave written informed consent
before the implantation procedure.
Echocardiographic evaluation
Each patient underwent transthoracic and multiplane
transesophageal echocardiographic examination. For pre-
interventional diagnosis, peri-interventional guidance,
and post-interventional follow-up, an HP SONOS 5500
(Hewlett-Packard, USA) echocardiography system with a
S4 transducer using the harmonic mode (transmitting fre-
quency of 2.1 MHz and a receiving frequency of 4.2
MHz), and the 5 MHz multiplane transoesophageal
probe, or the VIVID FIVE system (General Electric-
Vingmed Ultrasound, Horton, Norway) with a 5 MHz
multiplane transesophageal probe were used. The tran-
sthoracic studies were performed in left lateral recumbent
position with non-contrast second harmonic imaging
(Octave mode: transmit frequency of 1.7–1.9 MHz and a
receive frequency of 3.4–3.8 MHz). Images were obtained
using a 2.5-MHz phased array transducer at a depth of 12–
16 cm in all standard apical and parasternal views. The
contrast agent used during transesophageal echocardiog-
raphy was Echovist® (Schering AG Berlin, Germany) in
order to detect right-to-left shunt at rest and after Valsalva
maneuver.
In addition to standard transthoracic imaging and multi-
plane 2D transesophageal echocardiography, 3D
Table 1: Patient and Clinical Characteristics
Total 161
Female sex [no] 83
Age [years]
• Mean ± SD 46.8 ± 11
• Range 19–78
Atrial septal anatomy
• PFO only 79
• PFO and ASA 35
• ASD only 34
• ASD and ASA 13
PFO-size [mm]
• Mean ± SD 11 ± 5
• Range 5–14
ASD-size [mm]
• Mean ± SD 13 ± 6
• Range 6–26
Thromboembolic index event before – n (%) 144 (89)
• CVA 77 (48)
• TIA 62 (38)
• Peripheral embolism 5 (3)
Follow-up period [months]
• Mean ± SD 17 ± 11
• Range 13–19
PFO = patent foramen ovale; ASD = atrial septal defect; CVA = cerebrovascular accident; TIA = transient ischemic attack; ASA = atrial septal 
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transesophageal echocardiography was performed to vis-
ualize the interatrial septum in patients with ASD since
November 2001 (n = 16). We used the VIVID FIVE system
(General Electric-Vingmed Ultrasound, Horton, Norway),
which has the capability for acquisition of serial cross sec-
tional echocardiographic images by a 5-MHz multiplane
transesophageal probe. The system was connected with
EchoPac (Compac-PC, Windows 2000) for off-line analy-
sis and 3D reconstruction, using the Echo-Pac-3D for
Windows software (version 1.02). Serial cross sectional
images with increments of 2° were acquired with cardiac
and respiratory cycle gating. Cardiac cross-sections were
formatted in their correct sequence according to their elec-
trocardiogram and respiratory phase in cubic data sets.
The image data were converted from polar to Carstesian
coordinate format and interpolated to "fill the gaps"
between sequential cross-sections.
Image display
The interatrial septum was imaged from different compu-
ter-generated views, that allowed for identification of the
shape, size, rim and cardiac cycle dependent shape
changes (Fig. 1).
Computer reconstructed two-dimensional images of a large secundum atrial septal defect (upper panels and left lower panel)  and 3D echocardiographic reconstruction (right lower panel) Figure 1
Computer reconstructed two-dimensional images of a large secundum atrial septal defect (upper panels and left lower panel) 
and 3D echocardiographic reconstruction (right lower panel). LA, left atrium; RA, right atrium.
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Volume-rendered display
Once an appropriate cut plane had been chosen, a thresh-
old value was selected to differentiate cardiac structure
from the blood pool and background, and a gradient
shading algorithm enhanced the views.
Image analysis
From dynamic, volume rendered images looking at the
defect from the left and right atrium, specific frames with
axis corrected visualization of the defect were defined, and
areas were calculated by direct drawing. The echocardio-
grams were analyzed by two experienced observers.
Implantation procedure
Venous access was gained via the right femoral vein, and
the interatrial communication was passed under fluoro-
scopic guidance with a 7F multipurpose catheter. In all
patients, stretch size of the PFO or ASD was determined
with an NMT (NMT Medical Corp.) sizing balloon or
Equalizer Ballon Catheter 7F (Boston Scientific MEDI-
TECH, Natick, MA, USA). The multipurpose catheter was
exchanged for a 7F to 11F transseptal sheath via a standard
0.035-in exchange wire for Cardioseal or Rashkind device
implantation, 7F or 8F for other devices. The occluder was
delivered through the transseptal sheath and placed
within the PFO or ASD without puncture of the interatrial
wall under fluoroscopic guidance according to the device-
specific implantation recommendations. The occluder
was advanced through the sheath into the left atrium until
the left atrial part of the device was unfolded. The whole
unit was withdrawn under fluoroscopic and /or echocar-
diographic guidance against the interatrial septum, the
right atrial part of the device was unfolded after contrast
angiography in order to check the correct position. Before
the release of the occluder, the device position was
checked again by right atrial contrast angiography in order
to delineate the atrial septum. Transesophageal echocardi-
ographic monitoring was performed in all patients with
large ASD. At the end of the procedure, the transseptal
sheath was removed, and hemostasis was achieved by
manual compression.
Out of 43 patients receiving Rashkind devices, 27 patients
received anticoagulation initially with heparin and over-
lapping with phenprocumon until the target INR between
2.5 and 3.0 was reached and oral anticoagulation was con-
tinued for 3 to 6 months. All other patients were treated
with aspirin 100 mg once daily and Clopidogrel bisulfate
75 mg once daily for 3 to 6 months. All patients received
antibiotic prophylaxis (Flucloxacillin 2 g IV) during the
procedure.
Follow-up evaluation
Follow-up visits after 6 weeks, and 6 and 12 months
included ECG, transthoracic echocardiography. Trans-
esophageal echocardiography with intravenous contrast
and fluoroscopic contrast were performed after 6 weeks
and 12 months. Any recurrent thromembolic events were
considered as primary end points of the study. Patients
with suspected thromboembolic recurrence were re-exam-
ined by a neurologist, and whenever possible, an imaging
study (MRI or CT) was repeated.
Definitions
Atrial septal aneurysm was defined with an excursion of >
10 mm of the interatrial septum. A PFO was defined as the
appearance of microbubbles across the interatrial septum
(spontaneous or with Valsalva maneuver) and the
absence of a left-to-right shunt with color Doppler tech-
nique. An ASD was defined as a left-to-right shunt in the
color Doppler in addition to the right-to-left shunt during
contrast application.
Procedural complications were defined as any adverse
event that occurred within 24 hours of device implanta-
tion. The dose area product of radiation was expressed as
multiples standard for 2-plane of chest x-rays (1.2
Gy·cm2) according to the German Bundesamt für Strahl-
enschutz http://www.bfs.de.
Statistical analysis
Values are expressed as mean ± standard deviation (SD)
unless indicated otherwise. Subgroups were compared by
parametric or non-parametric tests (t-tests and Wilcoxon-
Mann-Whitney tests, resp.). More than 2 groups were ana-
lysed using ANOVA (symmetrically distributed observa-
tions) or Kruskal-Wallis test (otherwise). Post-hoc tests
were performed (if significant differences proved to be
global) with the help of multiple tests or pair-wise com-
parisons (with the same error of the 1st kind in 3 groups –
closed test procedure). Statistical significance was
assumed at a value of P < 0.05.
Results
Patient demographics are summarized in Table 1.
Radiation exposure
The mean area dose product per patient for the implanta-
tion of the devices was 150,3 Gy cm-2 (SD 77.6; range: 29
– 441 Gy cm-2) and 4.0 Gy cm-2 for follow-up after 6
weeks and 12 months. The mean fluoroscopy time for the
implantation of the devices was 18.5 min (± 6.3; range 5
– 44 min). The multiples of chest x-ray were 125.2 (mean
± 64.6, range 24.2 – 367.5).
Procedural success, complications and follow-up
The implantation was technically successful in all of the
161 patients (100%). There were 3 procedural complica-
tions (1.8%), which are summarized in Table 2. During a
follow-up of 324.3 patient years (range, 14 to 28Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/5
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months), recurrent embolic events occurred in only 1
patient (0.6%). In one patient the device was surgically
removed because of device thrombosis without embo-
lism. The follow-up time free of severe complications
(device thrombosis, malfunction, device explantation) is
described in (Figure 5). The ASDOS device had a sinifi-
cantly higher complication rate than all other devices. The
complication rate of the Amplatzer, Rashkind and Cardi-
oseal devices did not differ significantly during follow-up.
RASHKIND device
Out of 43 patients there was only one procedural compli-
cation with too early disconnection of the device, but it
could be removed transvasally. Subsequently, another
device was successfully implanted, and there were no
complications during the follow-up period (at least 12
months). A residual shunt was seen in one patient.
ASDOS (Atrial-Septal-Defect-Occlusion-System); (Sulzer Osypka, 
Rheinfelden, Germany)
Late complications occurred in 4 of 7 patients: pericardial
perforation of the device (n = 1); disconnection of the
device (n = 1); thrombosis on the left atrial part despite
anticoagulation with an INR between 2.5–3.0 (n = 1); dis-
location of the left atrial part (n = 1). Therefore, all
remaining ASDOS devices were surgically removed pro-
phylactically and the defect was surgically closed. The fur-
ther use of this device was stopped [37].
CardioSEAL™ Septal Occluder Implant (Nitinol Medical 
Technologies, Inc. Mass. USA)
In one patient, a tachyarrhythmia occured during implan-
tation. In 3 of 33 patients atrial fibrillation were observed
during late follow-up, which could converted into sinus
rhythm with medical treatment in two patients and with
electrical cardioversion in one patient. In another patient,
a cerebrovascular embolism (with TIA) occurred during
follow-up due to a large thrombus on the left atrial side of
the device despite anticoagulation with target INR
between 2.5–3.0, the device was surgically removed and
the defect was closed.
CardioSEAL™ Occluder Starflex (Nitinol Medical Technologies, Inc. 
Mass. USA)
In 2 patients of 11 patients, 6 weeks after device implan-
tation transesophageal echocardiography detected a large
left atrial thrombus, which was surgically removed and
the intra-atrial defect was closed.
Amplatzer Septal Occluder and Amplatzer PFO Occluder (AGA 
Medical Corporation, Golden Valley; MN. USA)
In one patient with Amplatzer PFO Occluder, an air
embolism without stroke occured in one patient. There
was no complication during late follow-up in all 8 + 59
patients.
Echocardiographic findings
Color Doppler and contrast transesophageal echocardiog-
raphy demonstrated complete occlusion in 159 of 161
patients after 1 month. In two patients who had ASD clo-
sure, an interatrial contrast passage was demonstrated
during a Valsava maneuver after 6 months. Therefore a
second occluder device was additionally implanted with-
out complications (patient 1: additional to Cardioseal
Starflex: Amplatzer PFO Occluder; patient 2: additional to
Rashkind device: Cardioseal Septal Occluder), and with-
out residual right-to-left shunt 4 weeks after the
procedure.
Three dimensional echocardiography was performed and
was sufficient for analysis of interatrial defects in 26 of 27
patients before and after device implantation (all with
ASD) and in additional 21 of 23 patients after closure of
the PFO. Three dimensional imaging allowed the
visualisation of the device surfaces from both sides, the
area calculation of the defects and the visualisation in all
image planes and angles (Fig. 1), which was not possible
with two-dimensional echocardiography. The mean addi-
tional acquisition time for 3D echocardiography is 7 min
Table 2: Complications, residual shunts and recurrence of embolism
Total Procedural 
complications
Late complications Residual shunt 
(after 6 months)
Recurrence of 
embolism
Amplatzer PFO Occluder 59 1
Amplatzer Septal Occluder 8
CardioSEAL Septal Occluder 33 1 1
CardioSEAL Occluder Starflex 11 2 1
Rashkind 43 1 1
ASDOS 74
161 3 6 2 1Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/5
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(± 3 min) and the mean off-line reconstruction time is 14
min (± 10 min). Intra-observer variability for 3D measure-
ments was 3%, the absolute mean difference was 0.6 mm
for ASD maximal diameter. Inter-observer variability for
3D echocardiographic measurements was 5%; the abso-
lute mean difference was 0.4 mm for ASD maximal
diameter.
The area of the defects changed significantly during the
cardiac cycle from 112 ± 54 mm2 to 46 ± 26 mm2 (P <
0.001). The percentage change ranged from 22.1% to
74.6%, with a mean of 51.2%. The measurement of the
length of the anterior rim was only possible with 3D
echocardiography: with change during the cardiac cycle
from 34 ± 17 mm to 13 ± 7 mm, the percentage change of
the distance ranged from 25.3% to 80.6%, mean 65.4%.
The was no correlation between percentage change in the
defect areas measured by two- and three-dimensional
echocardiography (R2 = 0.132).
Discussion
In this article, we present our experience with percutane-
ous transcatheter closure of an interatrial communication
using different septal occluder systems in adult patients.
Device type – complications
The success rate strongly depends on the type of occluder
system. Complete PFO closure at follow up can be
expected in 90–95% of patients utilising CardioSeal or
Amplatzer occluder [5]. There are continuous databases
which report an annual recurrent combined stroke/TIA
event rate of less than 4% for the CardioSeal [23]. In con-
trast to these data, we demonstrated the best results with
the Amplatzer and Rashkind devices.
The complications in our patient population mainly
occurred in those patients, which have received the
ASDOS occluder device. Complications in ASDOS-
patients were reported previously [24]. For all other
devices, the implantation has a low risk-benefit ratio
(lowest for Amplatzer and Rashkind) and the complica-
tion rate during follow-up was low.
Radiation exposure
Interventional fluoroscopic procedures produce the high-
est radiation doses of all medical imaging procedures and
add to the lifetime risk of fatal cancer [25,26]. The fluor-
oscopy time and dose-area-product for the implantation
of the intra-atrial devices has a high variation in our
patient population. Increasing routine and experience in
the implantation procedures will hopefully reduce the
radiation doses. New techniques, icluding on-line 3D
echocardiography, intracardiac echocardiography) might
reduce radiation time in the future. Intracardiac echocar-
diography might even further reduce fluoroscopy time
[27]. Furthermore, studies adressing device implantation
in adults by echocardiographic guidance alone without
fluorscopy are currently performed [28].
2D and 3D echocardiography
3D echocardiography provides morphological details in
different clinical entities in vivo in the quality of an intra-
operative or pathologic examination [21].
3D echocardiography allows unique en face views of the
atrial septum (Fig. 1) and the closure devices (Fig. 2), and
has the ability to measure the maximal diameter and the
systolic and diastolic areas of the defect [30,31]. This is a
clear advantage of 3D echocardiography, because 2D
echocardiography can not display the diastolic-systolic
difference of the intraatrial defect area.
3D echocardiography demonstrated the great variability
of the shape of the ASD as described before [30,32]. This
variability might alter the accuracy of diameter and area
calculation by 2D echocardiography and the measure-
ment of the rim by 2D echo. In patients with complex or
elongated shapes of the ASD, 2D echo will underestimate
the defect maximal diameter. The ASD area changed sig-
nificantly during the cardiac cycle, with a maximum size
in late ventricular systole and a minimum size in late ven-
tricular diastole [30-32]. Changes in defect areas were
quite variable among different patients. This variable
change has important consequences for the different
methods of treatments, i.e. suitability of transcatheter clo-
sure devices. As previously described [32] we could also
3D transesophageal image of a large secundum atrial septal  defect, the image shows the defect area from the left atrium;  Ao, ascending aorta Figure 2
3D transesophageal image of a large secundum atrial septal 
defect, the image shows the defect area from the left atrium; 
Ao, ascending aorta.
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demonstrate, that the changes in defect area were not only
parallel to the heart axis from the base to the apex, but
also perpendicular to the axis. All defect areas changed
symmetrically and concentrically with a similar shape.
Neither the age of the patient, the size of the defect, the
heart rate, nor the amount of volume overload affected
the extent of contraction [32], although other groups
demonstrated reduced contraction in older patients [33].
The degree of contraction cannot be measured accurately
with two dimensional echocardiography [32]. For the esti-
mation of dynamic changes in the defect area, 3D echo
has additional properties that are lacking with conven-
tional 2D echocardiography: 3D echo provides the angle
of the defect axis, and allows cross sectional imaging in
any plane.
A better understanding of the dynamic nature of the
defects using three dimensional echocardiography may
improve the closure rates and may overcome the prob-
lems of deployment, residual leaks and the long term cure
rates [28].
Closure of a large ASD that extends into the inferior sinus
venosus and has no posteroinferior rim is problematic
using occluder devices. A large ASD with an absent anter-
osuperior rim can be closed, but requires special tech-
niques and exact information about extent and location of
the rim. 3D echocardiography is the ideal technique to
provide this information, whereas 2 D echocardiography
requires the mental reconstruction into 3D information.
The relatively short acquisition and off-line reconstruc-
tion times for 3D echocardiography adds to its clinical
usefulness.
Other authors have found 3D echo useful in different clin-
ical settings [34-37]. New transthoracic techniques with
on-line reconstruction systems and off-line quantification
will further improve its clinical usefulness.
Limitations
The 3D datasets we used always contained motion arte-
facts, as the serial cross sectional echocardiographic data
are acquired during different times of the cardiac cycle.
Conclusions
Percutaneous closure of interatrial communications
appears to be a promising technique in the secondary pre-
vention of recurrent systemic thrombembolic events in
patients with ASD and PFO. Two dimensional and three
dimensional transesophageal echocardiography is feasi-
ble and useful in the pre- and postprocedural diagnosis.
Three dimensional echocardiography provided new infor-
mation on the dynamic nature of secundum atrial septal
defects. The amount of contraction had a strong individ-
ual variability.
3D transesophageal image of the Amplatzer PFO Occluder  (arrow), the image shows the surface of the left atrial part of  the device Figure 3
3D transesophageal image of the Amplatzer PFO Occluder 
(arrow), the image shows the surface of the left atrial part of 
the device.
Ao
Original percutaneous PFO occlusion device: Amplatzer PFO  Occluder (AGA Medical, Golden Valleey, Minnesota, USA),  view of the left atrial surface Figure 4
Original percutaneous PFO occlusion device: Amplatzer PFO 
Occluder (AGA Medical, Golden Valleey, Minnesota, USA), 
view of the left atrial surface.Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/5
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In the future, better detection of defect borders using real
time three dimensional echo may overcome the problems
related to direct measurement.
Prospective studies comparing percutaneous closure of
ASD and PFO with antithrombotic and anticoagulation
medications will define its future therapeutic value.
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